<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00376584</url>
  </required_header>
  <id_info>
    <org_study_id>0524A-023</org_study_id>
    <secondary_id>MK0524A-023</secondary_id>
    <secondary_id>2006_504</secondary_id>
    <nct_id>NCT00376584</nct_id>
  </id_info>
  <brief_title>Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)</brief_title>
  <official_title>A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Study to Evaluate the Efficacy of MK0524 to Improve Tolerability of Extended Release Niacin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This is a 12-week clinical trial in lipid clinic patients for whom niacin therapy is
      appropriate to evaluate the efficacy of MK0524 to improve the tolerability of
      extended-release niacin. There will be 6 scheduled clinic visits and 3 treatment arms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Flushing Severity Score (GFSS) during 7 days of treatment</measure>
    <time_frame>during 7 days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience at Least 1 Adverse Event</measure>
    <time_frame>up to 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Discontinued from the Study Due to an Adverse Event</measure>
    <time_frame>up to 10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">825</enrollment>
  <condition>Hypercholesteremia</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Placebo → MK-0524A 2g</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A Placebo for 5 days (drug holiday) followed by MK-0524A 2 g for the remainder of the study (7 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo → Extended Release (ER)-Niacin 2g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A Placebo for 5 days (drug holiday) followed by ER-Niacin 2g for the remainder of the study (7 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0524A 2g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A 2g for the remainder of the study (approximately 2 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0524A</intervention_name>
    <arm_group_label>Placebo → MK-0524A 2g</arm_group_label>
    <arm_group_label>MK-0524A 2g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ER Niacin</intervention_name>
    <arm_group_label>Placebo → Extended Release (ER)-Niacin 2g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo → MK-0524A 2g</arm_group_label>
    <arm_group_label>Placebo → Extended Release (ER)-Niacin 2g</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is appropriate candidate for niacin therapy

          -  Patients with evidence of ischemic cardiovascular disease must be on a statin and have
             LDL-C &lt;130 mg/dL at V1

          -  Patients with diabetes mellitus and no evidence of ischemic cardiovascular disease
             must have LDL-C &lt;130 mg/dL at V1

          -  Non-diabetic patients with 2 or more risk factors for coronary heart disease and no
             ischemic cardiovascular disease must have LDL-C &lt;160 mg/dL at V1

          -  Patient has TG &lt;500 mg/dL (5.65 mmol/L) at V1

          -  A patients historic serum or plasma lipid values measured within 6 months from Visit 1
             may be used to meet lipid inclusion criteria

          -  ALL OTHER PATIENTS DO NOT REQUIRE SPECIFIC LIPID ENTRY CRITERIA

        Exclusion Criteria:

          -  Patients with unstable doses of medications

          -  Pregnant or lactating women, or women intending to become pregnant are excluded

          -  Patients with diabetes mellitus that is poorly controlled, unstable or newly diagnosed

          -  Patients with: chronic heart failure, uncontrolled/unstable cardiac arrhythmias,
             unstable hypertension, active or chronic hepatobiliary disorder or hepatic disease,
             HIV positive, gout (within 1 year)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2006</study_first_submitted>
  <study_first_submitted_qc>September 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2006</study_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Hypercholesteremia</keyword>
  <keyword>Mixed Hyperlipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

